3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gastrointestinal
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Carcinoma, Non-Small-Cell Lung
2
Squamous Cell Carcinoma of Head and Neck
1
Solitary Fibrous Tumors
1
Sarcoma
1
Ovarian Neoplasms
1
Lung Neoplasms
1
Liposarcoma
1
Histiocytoma, Malignant Fibrous
1
Fallopian Tube Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Dermatofibrosarcoma
1
Colorectal Neoplasms
1
Interventions
Specimen Handling
4
Radiotherapy
4
Radiation
4
Nivolumab
4
pembrolizumab
3
Magnetic Resonance Spectroscopy
3
Ipilimumab
3
Doxorubicin
3
CTLA-4 Antigen
3
Biopsy
3
talimogene laherparepvec
1
peposertib
1
pazopanib
1
liposomal doxorubicin
1
fludarabine
1
cabozantinib
1
aldesleukin
1
X-Rays
1
Trabectedin
1
Ifosfamide
1
Histamine H2 Antagonists
1
Famotidine
1
Dactinomycin
1
Cyclophosphamide
1
BO-112
1
Angptl4 protein, mouse
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Histiocytoma, Malignant Fibrous
×
Histamine H2 Antagonists
×
90 days
×
Clear all
NCT06789172
2026-05-22
INVOKE
Epkin
Phase 1
Recruiting
166 enrolled